Viking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2023 Earnings Conference Call April 26, 2023 4:30 PM ET

Company Participants

Stephanie Diaz - Manager of Investor Relations

Brian Lian - Viking’s President and CEO

Gregory Zante - CFO

Conference Call Participants

Steven Seedhouse - Raymond James

Joon Lee - Truist Securities

Annabel Samimy - Stifel

Jay Olson - Oppenheimer

Andy Hsieh - William Blair

Yale Jen - Laidlaw & Co

Justin Zelin - BTIG

Nazibur Rahman - Maxim Group

Operator

Welcome to the Viking Therapeutics First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this conference call is being recorded today, April 26, 2023. I would now like to turn the conference over to Viking’s Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.

Stephanie Diaz

Hello and thank you all for participating in today’s call. Joining me today is Brian Lian, Viking’s President and CEO; and Greg Zante, Viking’s CFO. Before we begin, I would like to caution that comments made during this conference call today, April 26, 2023, will contain Forward-Looking Statements under the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking’s expectations regarding its development activities, time lines and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance.

These forward-looking statements speak only as of today’s date, and the Company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the Company’s filings with the Securities and Exchange Commission concerning these and other matters.

I will now turn the call over to Brian Lian for his initial comments.

Brian Lian

Thanks, Stephanie, and good afternoon to everyone dialed in by phone or listening on the webcast. Today, we will review our financial results for the first quarter of 2023 and provide an update on recent progress with our clinical programs and operations. The first quarter of 2023 was an exciting time at Viking with important progress announced across multiple clinical programs.

With respect to VK2809, our lead thyroid hormone receptor beta agonist for the treatment of NASH and fibrosis, early in the quarter, we announced completion of enrollment in our Phase 2b VOYAGE trial and we expect to announce top line data from the primary endpoint in this study in the second quarter of 2023.